IL6

Chr 7MultiSomaticADAR

interleukin 6

Also known as: BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2, IFNB2, IL-6

This gene encodes a cytokine that functions in inflammation and the maturation of B cells. In addition, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The protein is primarily produced at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of this gene is implicated in a wide variety of inflammation-associated disease states, including suspectibility to diabetes mellitus and systemic juvenile rheumatoid arthritis. Elevated levels of the encoded protein have been found in virus infections, including COVID-19 (disease caused by SARS-CoV-2). [provided by RefSeq, Aug 2020]

Primary Disease Associations & Inheritance

{Crohn disease-associated growth failure}MIM #266600
Multi
{Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}MIM #108010
Somatic
{Kaposi sarcoma in HIV+, susceptibility to}MIM #148000
AD
{Rheumatoid arthritis, systemic juvenile}MIM #604302
{Type 1 diabetes mellitus}MIM #222100
AR
{Type 2 diabetes mellitus}MIM #125853
AD
60
ClinVar variants
30
Pathogenic / LP
0.32
pLI score
12
Active trials
Clinical SummaryIL6
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.24) despite low pLI — interpret in context.
📋
ClinVar Variants
30 Pathogenic / Likely Pathogenic· 21 VUS of 60 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.75LOEUF
pLI 0.315
Z-score 2.04
OE 0.24 (0.100.75)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.00Z-score
OE missense 1.00 (0.861.17)
112 obs / 112.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.24 (0.100.75)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.00 (0.861.17)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.99
01.21.6
LoF obs/exp: 2 / 8.4Missense obs/exp: 112 / 112.1Syn Z: 0.03

ClinVar Variant Classifications

60 submitted variants in ClinVar

Classification Summary

Pathogenic28
Likely Pathogenic2
VUS21
Likely Benign4
Benign5
28
Pathogenic
2
Likely Pathogenic
21
VUS
4
Likely Benign
5
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
28
0
28
Likely Pathogenic
0
0
2
0
2
VUS
0
12
9
0
21
Likely Benign
0
2
0
2
4
Benign
0
3
1
1
5
Total01740360

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

IL6 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

IL6-related Kaposi sarcoma

definitive
ADUndeterminedAltered Gene Product Structure
Skin
G2P ↗
missense variantinframe deletioninframe insertion

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

INTERLEUKIN 6; IL6
MIM #147620 · *

{Crohn disease-associated growth failure}

MIM #266600

Molecular basis of disorder known

Multifactorial

{Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}

MIM #108010

Molecular basis of disorder known

Somatic mutation

{Kaposi sarcoma in HIV+, susceptibility to}

MIM #148000

Molecular basis of disorder known

Autosomal dominant

{Rheumatoid arthritis, systemic juvenile}

MIM #604302

Molecular basis of disorder known

{Type 1 diabetes mellitus}

MIM #222100

Molecular basis of disorder known

Autosomal recessive

{Type 2 diabetes mellitus}

MIM #125853

Molecular basis of disorder known

Autosomal dominant
📖
GeneReview available — IL6
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

COVID-19

Arginine Replacement Therapy in COVID-19

RECRUITING
NCT05855330Phase PHASE2Emory UniversityStarted 2024-01-08
Arginine Hydrochloride
Decompensated Cirrhosis

Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis

NOT YET RECRUITING
NCT06533852Phase PHASE3Consorcio Centro de Investigación Biomédica en Red (CIBER)Started 2024-12
Fecal Microbiome Transplantation (FMT)FMT Placebo
Pre-FrailtyAging

Exploratory Study on a Multi-nutrient Supplement and Exercise Program for Improving Health Markers Associated to Longevity in Pre-frail Adults

RECRUITING
NCT07454616Phase NANational University of SingaporeStarted 2025-09-22
Supervised exercise programa balanced micronutrient blend
ResilienceCognitive Function and Well-BeingMuscle Function, Handgrip Strength Test

Aging Resilience Through Microbiota Optimization and Regulation

ACTIVE NOT RECRUITING
NCT06649981Phase PHASE1Gonzalo Jorquera, PhDStarted 2025-01-10
FMT capsulePlacebo Capsule(s)
Non-Alcoholic Fatty Liver DiseaseCardiovascular Diseases

EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases

RECRUITING
NCT06392828IMDEA FoodStarted 2024-04-15
Rectal Cancer PatientsObesity &Amp; OverweightLocally Advanced Rectal Cancer (LARC)

Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer

NOT YET RECRUITING
NCT07314528Phase PHASE2St. James's Hospital, IrelandStarted 2026-04
GLP-1 receptor agonistTotal neoadjuvant therapy (TNT)
High-grade GliomaWHO Grade Ⅳ Glioma

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

RECRUITING
NCT06482905Phase PHASE1Tcelltech Inc.Started 2024-09-04
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
GanglioneuroblastomaHigh Risk Neuroblastoma

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

ACTIVE NOT RECRUITING
NCT03786783Phase PHASE2National Cancer Institute (NCI)Started 2019-03-04
Autologous Hematopoietic Stem Cell TransplantationCarboplatinCisplatin
Triple-negative Breast Cancer

Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer

ACTIVE NOT RECRUITING
NCT06418126Phase NACentre Paul StraussStarted 2024-01-11
blood sampling before radiotherapyblood sampling after the fourth radiotherapy sessioncollection of acute toxicity (radiodermatitis)
Colorectal Cancer PreventionColorectal Adenoma

BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention

NOT YET RECRUITING
NCT07162337Phase NAMassachusetts General HospitalStarted 2026-03-01
Increased Plant-Based Diet and Decreased Animal-Based Diet
Graves' Disease

In Vivo CAR-T for Refractory Graves' Disease

RECRUITING
NCT07333677Phase EARLY_PHASE1Shanghai Zhongshan HospitalStarted 2026-01
In Vivo CAR-T Therapy
Alcohol Use Disorder

The Efficacy of Probiotics for the Treatment of Alcohol Use Disorder Among Adult Males

NOT YET RECRUITING
NCT05830708Phase NAUniversiti Sains MalaysiaStarted 2023-05-01
Lactobacillus sp. probioticAcceptance and commitment therapyPlacebo